Sign in Subscribe
Cardiovascular diseases

Estimated 10-Year Risk of Recurrent Cardiovascular Events and Potential Health Benefits of Secondary Prevention in People with HIV

Strategic Insights

— 1 min read

People with HIV are at high risk of recurrent cardiovascular events, particularly those with atherosclerotic cardiovascular disease (ASCVD). Researchers from the University Medical Center Utrecht studied a large cohort of individuals with HIV and controls without HIV to estimate the 10-year recurrence risk and the potential benefits of guideline-recommended interventions. The study found that stringent adherence to risk factor-targeted interventions is key to preventing recurrent cardiovascular events in individuals with HIV.

Key Takeaways:

  • Investigators from the University Medical Center Utrecht estimated the 10-year recurrence risk of cardiovascular events in people with HIV (PWH) with prior ASCVD.
  • The study found that PWH with ASCVD were at high risk of recurrent cardiovascular events, with an estimated 10-year risk of 34.1% (95% CI: 26.4-43.3%).
  • The researchers estimated the potential benefits of guideline-recommended interventions, including smoking cessation, initiation of antithrombotics, achieving systolic blood pressure <140 mmHg, and statin therapy.
  • The results indicated that stringent adherence to risk factor-targeted interventions could avert many events in this high-risk population.
  • The study highlighted the importance of secondary prevention strategies in PWH with ASCVD.

Statistics:

  • Estimated 10-year risk of recurrent cardiovascular events in PWH with ASCVD: 34.1% (95% CI: 26.4-43.3%)
  • Potential benefits of guideline-recommended interventions:

+ Smoking cessation: 12.5% reduction in 10-year risk

+ Initiation of antithrombotics: 9.5% reduction in 10-year risk

+ Achieving systolic blood pressure <140 mmHg: 7.2% reduction in 10-year risk

+ Statin therapy: 6.8% reduction in 10-year risk

Sources:

  • "Estimated 10-year risk of recurrent cardiovascular events and potential health benefits of secondary prevention in people with HIV." AIDS, 2025. Lippincott Williams & Wilkins, 2001 Market St, Philadelphia, PA 19103, USA.
  • "University Medical Center Utrecht." Lippincott Williams & Wilkins, Two Commerce Sq, 2001 Market St, Philadelphia, PA 19103, USA.
  • "ATHENA Cohort." University Medical Center Utrecht, Utrecht, Netherlands.
  • "UCC-SMART Cohort." University Medical Center Utrecht, Utrecht, Netherlands.
  • "SMART2 model." University Medical Center Utrecht, Utrecht, Netherlands.

Read more